FDA OK’s Novavax COVID Vaccine For Ages 12 to 17
Novavax Friday announced its COVID-19 vaccine was authorized for emergency use by the U.S. Food and Drug Administration for adolescents between 12 and 17.
Novavax’s two-dose vaccine for those 18 and older received emergency approval from the FDA in July.
“Having more vaccine options for use in both adults and adolescents, like the Novavax COVID-19 Vaccine, Adjuvanted will hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of COVID-19 with the start of fall and the back-to-school season,” said Novavax president and CEO Stanley C. Erck. “We hope that our vaccine, developed using an innovative approach to recombinant protein vaccine technology, may have a special role in adolescent vaccination based on parents’ and caregivers’ familiarity with protein-based vaccines used in other disease areas.”
For more information, read CNBC here and Novavax’s statement here.
